Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus
Conditions
Interventions
After randomization, administration is carried out in the following manner. The administration period is 24 weeks.
A. Swinney group: Oral administration twice a day, 100 mg once a day for sweet potato
Sponsors
Arima Hiroshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetes HbA1c >= 6.5% Serum LDL >= 120 mg/dl No DPP4 inhibitors for latest 3 months No antidiabetic medication or no change in medication for the latest 3 months 20 y.o. or older Written agreement is obtainable from the patient
Exclusion criteria
Exclusion criteria: Type 1 diabetes Treatment with insulin, glinides, high doses of SU Patients with repetitive or unaware severe hypoglycemia Severe liver diseases Patients with hemodialysis Severe cardiac diseases or acute myocardial infarction within 6 months Severe anemia Severe pancreatitis Malignant diseases Uncontrolled endocrine diseases Severe infections or surgical treatment Severe diabetic complications Severe bowel diseases Alcohol addiction Pregnant or possibly pregnant women History of allergic reaction to DPP4 inhibitors Patients who a physician-in-charge considers is unsuitable for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood lipid fractions | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c, inflammatory marker, oxidative stress marker, cytokine | — |
Contacts
Public ContactTakeshi Onoue
Nagoya University Graduate School of Medicine
Outcome results
None listed